GW Pharma Impresses Analysts With Phase 3 Trial Data

Over the weekend, GW Pharmaceuticals PLC – ADR (NASDAQ: GWPH) presented additional data from its Phase III trials of Epidiolex in Lennox-Gastaut (LGS) and Dravet syndromes, at the American Epilepsy Society (AES) meeting.

Cantor Fitzgerald’s Elemer Piros maintained a Buy rating on the company, with a price target of $182.

Phase III Data

Piros mentioned that “both studies achieved robust reductions of their primary endpoint in drop seizures and convulsive seizures, respectively.”

Responder analyses presented by GW Pharma at the AES meeting showed that Epidiolex was successful in achieving significant separations from the placebo group.

For Dravet, while responder analyses was marginally short of statistical significant, the analyst noted that “separation was maintained along the curves,” while the safety data demonstrated “a greater incidence of somnolence, diarrhea and decreased appetite in Dravet, compared with LGS.”

Piros believes that overall, the data highlighted Epidiolex’s significant ability to treat two orphan pediatric epilepsy indications, with distinct patient population characteristics.

The stock closed Friday's session at $112.32, up nearly 3 percent.